Introduction
When interim clinical trial data are released, vigorous discussion frequently ensues, either supporting or lamenting the decision. Two recent early terminations of clinical trials in obesity and hypertension opened heated discussions about the scientific, societal, and economic consequences of prematurely stopping on-going studies and releasing interim clinical trial data. The Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects with Cardiovascular Risk Factors (LIGHT Study), sponsored by Orexigen and Takeda (https://clinicaltrials.gov/ct2/ show/NCT01601704?term=contrave&rank=5 (accessed 17 May 2016)) randomized 8910 obese individuals with risk factors for cardiovascular disease to Contrave (combination Naltrexone SR and Buproprion) vs. placebo. The primary endpoint was time to major adverse cardiovascular events (MACE). Controversy arose when these confidential interim results were released in a patent filing, after 25% of MACE events occurred, claiming that Contrave caused a 41% reduction in MACE (P , 0.0001). At the time of the interim analysis, the mean duration of drug exposure was 26.84 weeks in the placebo arm and 30.47 weeks in the Contrave arm; patients were to be enrolled on treatment for 3 -4 years. The release of this information was not authorized by the trial executive steering committee or the independent data monitoring committee (IDMC) and violated the FDA confidentiality terms of agreement. When 50% of MACE events occurred, the cardiovascular benefit seen earlier was gone (HR 0.88, 95% CI 0.66 -1.17). The trial steering committee halted the study, and the FDA required a second trial to be conducted (http://my.clevelandclinic.org/about-cleveland-clinic/newsroom/ releases-videos-newsletters/2015-5-12-clinical-trial-testing-safetyof-obesity-drug-contrave-halted (accessed 17 May 2016)).
The Systolic Blood Pressure Intervention Trial (SPRINT)-sponsored by the National Heart, Lung, and Blood Institute (NHLBI)-was an open label randomized controlled trial that examined whether intensive blood pressure reduction [systolic blood pressure (SBP) of ,120 mmHg] was superior to standard treatment (SBP target of ,140 mmHg).
1 Nine thousand three hundred and sixty-one patients were randomized and the primary endpoint was a composite of myocardial infarction, other acute coronary syndrome, stroke, heart failure, or death from cardiovascular causes. SPRINT was stopped early based on recommendations by the IDMC after the 3.26 years of the planned average of 5 years of follow-up. The final results demonstrated a 25% reduction in the primary outcome (HR 0.75 95% CI 0.64 -0.89, P , 0.001). These two early terminations present an interesting contrast. If extended follow-up can lead to a change in results as substantial as the one seen in the LIGHT Study, can we trust the results of SPRINT which was also stopped early? Why is the release of LIGHT study interim data viewed as compromising trial integrity, whereas the interim data from SPRINT are heralded as an important public health advance?
Scientific implications of releasing interim data
Confidentiality of clinical trial interim results is of critical importance. As noted by the FDA (http://www.fda.gov/OHRMS/ DOCKETS/98fr/01d-0489-gdl0003.pdf (accessed May 17 2016)) if a sponsor gains access to unblinded interim data, it may present substantial risk to the integrity of the trial and can potentially harm patients. If interim results are known, sponsors may be unable to manage the trial without introducing bias-for example to modify inclusion criteria or to adjust study protocol in order to achieve a desired trial result. Furthermore, a sponsor may inadvertently include results in communication to other groups or even the public-precisely what happened in the LIGHT Study. The impact of premature disclosure of interim results is unpredictable. Based on their own limited interpretation of the interim data, investigators may select only certain types of patients to enrol. Patients may demand to receive one treatment arm or drop out of the study altogether, wishing to cross over to a different arm. In any case, the integrity of the future trial data is compromised, as pointed out by the executive steering committee in announcing the decision to stop the LIGHT Study. A fundamental difference between the LIGHT Study and SPRINT lies in the fact that SPRINT was terminated at the recommendation of an IDMC. After thoroughly evaluating the interim data, taking into account stopping rules, study conduct, and potential risks and benefits of trial continuation, the SPRINT IDMC concluded that continuation of the trial would be unlikely to substantially change the interim results. It was, therefore, appropriate to stop the trial. Subsequent to the release of the interim results, future treatment decisions would be based on sound evidence, just as if SPRINT had been fully completed as planned.
The release of interim trial data may inform the decision making of patients and physicians. Release of interim data could restore equipoise and increase enthusiasm of investigators to enrol patients. While there is some validity in this viewpoint, release of early data poses significant risk to the scientific validity of a trial. Release of interim data should only be considered when the need to make results public far outweighs this risk.
Societal implication of releasing interim clinical trial data
The termination of the LIGHT study due to compromised scientific integrity meant that patient participants were exposed to the risks of experimental drug treatment without the benefit of having conclusive evidence of a finished trial. In addition, front line physicians are left waiting for the results of a new trial to help guide treatment in this high-risk population. In contrast, release and dissemination of SPRINT results, demonstrating that aggressive management of blood pressure resulted in fewer cardiovascular outcomes and death, could have helped physicians make better treatment decisions. Protection of confidentiality and careful examination of the interim data prior to its release by the IDMC accelerated the availability of these new findings and provided more options to patients sooner.
Early release of interim clinical trial data brings up a related issue of when and how such data should be disseminated. The SPRINT data was released on the web by the study sponsor (NHLBI), unbeknownst to trial investigators and prior to a peer reviewed publication. Arguments have been made that complete trial data should be released quickly to facilitate the implementation of potentially life-saving therapeutic strategies. However, the release of data prior to careful review by the investigators and a formal peer review-in the absence of a public health emergency-should be discouraged. 2 The decision when to release unexamined interim trial data should always weigh the benefits of expedient dissemination of the results against the risks associated with the lack of time for a thorough statistical analysis and peer review.
Economic consequence of releasing interim clinical trial data
The LIGHT Study was conducted to support commercialization of Contrave as a weight loss drug. Given the burden of obesity in the USA, this represents a significant economic market. Inclusion of interim results in the patent filling illustrates the potential economic and market response to positive news. Prior to the interim results being released, Orexigen was given a strong recommendation by a major US bank, Wells Fargo, due to the ongoing LIGHT Study. Following release of interim trial data, misplaced optimism by business analysts and investors resulted in a 32% increase in Orexigen shares. However, after termination of the LIGHT Study and the FDA requirement for a new clinical trial, Orexigen's stock lost over 75% of its value from its peak near March 2015 to October 2015.
Conclusion
In addition to monitoring patient safety in an ongoing clinical trial, the IDMC plays a major role in the orderly release of interim results. Both SPRINT and the LIGHT Study provide unique insights into the scientific, societal, and economic consequences of releasing interim clinical trial data. The response of the FDA towards Orexigen and the requirement to conduct an additional trial illustrate the potential consequence of releasing confidential interim data prior to adequate scientific review. Premature release of interim trial results, especially when not been recommended by an IDMC, can compromise the scientific process, reduce trial integrity, and put patients at risk.
